Details of Drug-Drug Interaction
| Drug General Information (ID: DDI9LGDMO7) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Insulin human (inhalation, rapid acting) | Drug Info | Pentamidine | Drug Info | |||||
| Drug Type | Hormones | Small molecule | |||||||
| Therapeutic Class | Insulin/Antidiabetic Agents | Antifungal Agents | |||||||
| Structure | |||||||||
| Mechanism of Insulin human (inhalation, rapid acting)-Pentamidine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Insulin human (inhalation, rapid acting) | Pentamidine | |||||||
| Mechanism | Inhaled human insulin | Interfere with the therapeutic efficacy of insulin | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin and/or oral antidiabetic agents, especially if they are elderly or have renal impairment. Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations. If hypo- or hyperglycemia occurs during pentamidine therapy, patients should initiate appropriate remedial therapy immediately, discontinue pentamidine therapy, and contact their physician. | ||||||||